Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Top CDMO Firms of 2020
A CDMO is a company that aids pharmaceutical firms on a contractual basis, which means they handle services ranging from initial drug development through to large-scale manufacturing of treatments. In 2020, the pharmaceutical industry is leaning heavily on CDMOs to help facilitate and expedite the process of creating, testing, and developing critical treatment solutions such as a potential COVID-19 vaccine. Here are the top ten CDMO firms of 2020:
1. Cambrex
Cambrex is one of the largest CDMO firms in the world, which forged its name in developing, testing, and building small-molecule active pharmaceutical ingredients. Over time, the firm built a name as a premier CDMO firm after a series of major acquisitions that solidified the firm’s expertise. In an interesting turn of events, Cambrex was purchased by Permira Funds, a private equity firm for $2 billion in late 2019, to help optimize the company.
2. Recipharm
Recipharm is a long-standing firm in the pharmaceutical space, having recently celebrated 25 years of business. Among one of the five largest CDMO firms in the world, the company has a global presence in all corners of the world and employs over 9,000 people. Recently, Recipharm has noted a dramatic growth in interest for the company’s chloroquine antiviral drug, which has been used to aid patients with coronavirus COVID-19.
3. Thermo Fisher Pantheon
Thermo Fisher is a tremendous firm dedicated to improving human health through consumables, systems, and services. Among the firm’s notable offerings is their CDMO services. Notably, Thermo Fisher has officially entered with the development of a $475 million cell therapy collaboration center in Princeton.
4. Samsung Biologics
Samsung Biologics is one of the largest CDMO firms in the world. In October 2018, Samsung Biologics opened up its third manufacturing plant which brings the firms’ annual production capacity to 360,000 liters a year. By 2020, Samsung Biologics estimates that it will produce 350 products across its three large-scale facilities.
5. Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies is a world-leading biologics CDMO that is actively working to help develop a future COVID-19 therapy through one of its Denmark-based facilities. Initially founded in the Netherlands in 1923, Diosynth saw success with its extraction of insulin from bovine pancreas, which still remains one of the company’s main products.
6. WuXi Biologics
WuXi Biologics is a Chinese headquartered CDMO firm that strongly leverages open-access, integrated technology platforms for drug development. A relatively recent firm, WuXi Biologics was founded in 2015 and went public on the Hong Kong stock exchange in 2017. While primarily based in China, the firm has expanded its global reach by building a specialized $394 million facility in Ireland.
7. Lonza
Lonza is a Switzerland-based CDMO firm that specializes in combining technological innovation with pharmaceutical manufacturing. Founded in 1897, Lonza is among one of the oldest continuously-running pharmaceutical companies in the world and has operations spread across 24 sites around the globe today.
8. Catalent
Catalent is a leading provider of advanced delivery technologies and development solutions for pharmaceutical solutions. Based in New Jersey, Catalent expanded its contract development and manufacturing presence through the aggressive purchases of multiple CDMOs, including Paragon Services ($1.2 billion) and Masthercell Global ($315 million).
9. Center for Breakthrough Medicines
The Center for Breakthrough Medicines is a new yet ambitious plan that seeks to become the world’s largest cell and gene therapy CDMO firm. As of early 2020, the firm sought to invest nearly $1.1 billion to redevelop a former GlaxoSmithKline site into a $500 million, 1.6 million square-foot campus in Pennsylvania. The good news for Center for Breakthrough Medicines is that development and manufacturing services oriented around gene therapy is largely untapped, which could give the firm significant future business.
10. Siegfried
Siegfried is a CDMO that offers a broad base of knowledge around complex oral and sterile creation of drugs and manufacturing. The firm has facilities based in Switzerland, Malta, Germany, and the U.S. that specialize in the manufacture and development of drug solutions.
https://www.pharmiweb.com/press-release/2020-06-26/top-cdmo-firms-of-2020
Dapper10,
You as the rest of us have reasons to be concern however when looking at the facts we have a very reasonable opportunity to create a paradigm shift in the pharmaceutical arena. It has not and will not be easy.
Let's look at the facts:
1. This is a penny stock which is a very risky investment.
2. The share structure make it less risky.
https://www.otcmarkets.com/stock/QNTA/security
3. QNTA has a Pre-IND application moving through the FDA protocols.
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
Scorpion Venom–Toxins that Aid in Drug Development: A Review
Published: 05 June 2018
https://link.springer.com/article/10.1007/s10989-018-9721-x
Abstract
Scorpion venom components have multifaceted orientation against bacterial, viral, fungal infections and other neuronal disorders. They can modulate the ion channels (K+, Na+, Cl-, Ca2+) of our body and this concept has been hypothesized in formulating pharmaceuticals. The triumphant achievement of these venom components as formulated anticancer agent in Phase I and Phase II clinical trials allure researchers to excavate beneficial venom components prohibiting DNA replication in malignant tumor cells. This review brings forth the achievements of Science and Technology in classifying the venom components as therapeutics and further application in drug product development.
Some select paragraphs:
As Antineoplastic Agent
Natural therapy, be it plant or animal derived, is occupying a vast section gradually as antineoplastic or cytotoxic agent due to the increasing uncontrollable adverse effects and ineffectiveness (possibly in metastasis and recurrence conditions) of chemotherapy and radiotherapy. The last three decades have seen attempts at detecting promising anticancer activity of animal venoms and toxins, some of which are presently under clinical trial (Lorenzo et al. 2012). Scorpion venom can be an amazing therapeutic agent against cancer as it inflicts upon cancer cells by arresting cell cycle at the S-phase thereby acting as a proliferative curb (Lorenzo et al. 2012; Ahluwalia and Shah 2014). SVTs are an inducer of apoptosis, aggravates neoplastic cells by amplifying production of nitric oxide, shows caspase-3 activity and depolarizes mitochondrial membrane (Ahluwalia and Shah 2014). Presently, positive results from in-vivo, in-vitro examination and Phase I and II clinical trials have proven SVTs as anticancer therapeutic agent (Kastin 2006). Cuba and Dominican Republic islands dwelling Blue (or Red) Scorpion (Rhopalurus junceus) is steadily gaining fame as an antineoplastic (Podnar 2015; Lorenzo et al. 2012) and is the thrust area for inquisitive researchers as numerous experiments are being executed on this arthropod to evaluate its pharmacological aspects. A protein constituent of this scorpion can abolish cancer cell proliferation (Ahluwalia and Shah 2014). Natives of the Caribbean island have been using this venom as an antitumor agent since 1997 (Podnar 2015). Novel discovery elucidates venom of this scorpion acts as a pain reliever and replenisher of energy in cancer patients (Lorenzo et al. 2012). A recent research work proposed by Díaz-García et al. (2017) on treatment recalcitrant Triple Negative Breast Cancer (TNBC) cell line (MDA-MB-231) demonstrated high cytotoxic activity of this arthropod venom breaking grounds for new therapeutic approaches (Díaz-García et al. 2017).
Traditionally used, venom of BMK scorpion is a possessor of multiple pharmacological activities including cancer and brain tumor (found effective against brain tumor cell line U251-MG) (Gomes et al. 2010; Díaz-García et al. 2013). Antitumor-analgesic peptide (AGAP) obtained by the application of recombinant DNA technology from this scorpion venom and expressed in Escherichia coli have confirmed to have both analgesic and antitumor activity in mice (Hmed et al. 2013). This peptide in a much lower dose compared to other antineoplastic agents has revealed of increasing antitumor activity with very few adverse effects (Oukkache et al. 2013). It can inhibit glioma cell proliferation by regulating their ion channels (Gomes et al. 2010). A peptide isolated from this scorpion has proven to be an anti-thrombotic (Petricevich et al. 2013) and another polypeptide having dose-dependent inhibitory activity arrested cell cycle of prostate cancer cell line DU-145 at G1 phase (Mishal et al. 2013; Zhang et al. 2009). Antiapoptotic role of this polypeptide can be due to highly expressed Bax (proapoptotic) or downregulated Bcl-2 (antiapoptotic) (Zhang et al. 2009). BMHYA1, an enzyme procured by extraction and purification from this scorpion hampers overexpression of CD44 surface marker in cancer cells (Hmed et al. 2013).
Scorpion venom component III (SVC III) has profound activity on the NF?B signaling pathway (has role on immunocyte generation, lymphocyte development and cell apoptosis) and thus selectively act upon human leukemia Jurkat cell line and THP-1 cells (Mishal et al. 2013). SVC III prevents cyclin D1 production and inhibits cell cycle at G1 phase (Mishal et al. 2013). Venom derived from Odontobuthus doriae is capable of platelet aggregation and possesses proteolytic enzymes (Mishal et al. 2013). It is a cytotoxic and apoptogenic agent as it has lactase dehydrogenase (LDH) (Mishal et al. 2013). This LDH can lower cell viability activating caspase-3 and mitochondrial depolarization (Ahluwalia and Shah 2014). Proteases derived from scorpion Mesobuthus gibbosus are proteolytic and gelatinolytic against human lung adenocarcinoma cell line (A549) (Mishal et al. 2013). An extensive research on venom from Blue Scorpion has drawn a conclusion that it can be an analgesic, anti-inflammatory and antitumor agent (Podnar 2015). To support this research, a drug named Vidatox 30CH has been formulated by Labiofam (a Cuban company) which reports of lessening the spread of cancer cells, increase life expectancy among cancer patients and has negligible side effects on patients (Podnar 2015). This scorpion venom induces apoptosis in HeLa cell line via both extrinsic and intrinsic pathway as p53 upregulation stimulates bax and downregulates bcl-2 (Díaz-García et al. 2013). A549 cell necrosis, as demonstrated by Díaz-García et al. (2013) was noticed along with p53 and bax downregulation when this scorpion venom was further examined (Díaz-García et al. 2013). Demetrio Rodriguez Fajardo, a 17-year-old Mexican has gained enough recognition by discovering a low molecular weight protein from scorpion venom and has developed a prodrug that can be used as a treatment against breast cancer (Takahashi 2014). He has even quoted that this protein has profound inhibitory activity on uterine cancer cells. This protein as a drug substance in the treatment of cancer is efficacious than conventional therapy even for diabetic patients (Takahashi 2014).
Future Prospects in Drug Discovery
The increment in newer techniques in the field of Research and Development (R&D) have led scientists to brood over to find cure from nature be it from plant or animal. A rough estimate brings forth the fact encompassing constant usage (nearly 40%) of Nature in the formulation of pharmaceuticals (Burke 2015). With the evolution of proteomics, genomics and transcriptomics, drug discovery from Nature and her resources has been a splendid approach. Though only a handful of ‘biologically important’ toxins could be derived from toxin-secreting animals still it calls for a revolution to fetch cure from these animals. Thus, it is mandatory to gain a thorough knowledge of the evolutionary history and the ecology of these animals before putting them into practice for the development of future pharmaceuticals (Casewell et al. 2013).
The process of establishing a chemical entity as a clinical candidate is an enormous and time-consuming process. Thousands of potential candidates are screened and only a few with potentialities emerge to face challenges in the pharmaceutical market. Till date, only a few venom peptide derived drugs have been approved by the FDA and furthermore are undergoing clinical trials or at the stage of preclinical development (Henney 2015). Captopril, ziconotide, atracurium, eptifibatide are some of the established drug products formulated from venom toxins (Harvey 2014). The synergistic property exhibited by K+ salt and peptide (scorpion prevenom and venom constituents) indicates the discovery of effective pharmaceuticals in the near future (Inceoglu et al. 2003).
Drugs and pharmaceuticals tend to have an affinity towards the ion channels of our body in conserving human physiology and usually, therapeutic advancement is being made by targeting these channels (Bennett and Guthrie 2003; Kaczorowski et al. 2008). Venom peptides being reservoir of chemical components are the tools to identify or characterize the function and structure of ion channels of our body. The rationale underlying the choice in targeting ion channels lies in their increased accessibility and success in delivering intended pharmacological activity upon being targeted by traditional or novel drug (Kaczorowski et al. 2008; Niemeyer et al. 2001). The failure of a drug candidate or an new drug application (NDA) often lies in the interaction with unrelated targets or channels (Kaczorowski et al. 2008). The key to ion channel drug discovery is embedded in the approaches that include in-vivo, in vitro targeting by the candidate drug product and other traditional drugs. Ziconotide, one such example, was developed to treat pain induced by intrathecal administration and by in vivo methods, was hence confirmed to treat pain as a calcium channel blocker (Kaczorowski et al. 2008).
QNTA stock price will eventually reverse.
Why?
No reason for the stock to go drop real low or rise real high.
There are a lot of catalysts in the works that will bring the stock price to its proper level.
Know what you own:
General Science
Escozine™ is a natural compound extracted from the Caribbean Blue Scorpion (Rhopalurus Princeps), which, in its original form, contains low molecular weight peptides, amino acids, proteins and 59 minerals. We have used modern technologies to isolate and filter the essential minerals. The extracted minerals have been polarized by a patented methodology (#US 8,097,284 B2) to increase the potency and binding preferences with abnormal cells. Escozine™ has several paths of influence that affect abnormal cells. The main compound induces Potassium (K+) 3-4 kDa, Sodium (Na+) 6- - 8 kDa and Chloride (Cl+) ionic channel inhibitors.
One of the main components of Escozine™ is a 36 amino acid peptide, which at pH 7 has a high positive charge. It blocks small-conductance chloride channels, and it also binds preferentially to abnormal cells, leaving the normal cells intact.
Patent
The basic principle described in the US Patent # US 8097284 B2 leads to molecular excitement of vibration produced by an electromagnetic field generator, leading to absorption of the quanta of energy for higher potency of the blue scorpion extract, which increases its effectiveness on overall human health at a deep cellular level. Specific frequencies, as well as harmonics, are used to achieve a resonance effect between the generated electromagnetic frequencies and the molecular frequency of the small molecular peptide, specific amino-acids and 59 essential minerals contained in the blue scorpion extract; the electromagnetic vibrational frequency acts as an energy donor and components contained in the scorpion extract act as an energy acceptor. This energy transfer gives more strength, force and potency to the Blue Scorpion extract.
Polarization Technology
A specifically generated monopole electromagnetic vibration creates a resonance effect with Escozine™’s main ingredients at the molecular level; this leads to absorption of energy and shortens the orbital movement of atoms which, in turn, leads to the increase of activity of polarized molecules, and intensifying their potency. Polarization increases the molecular vibration and is excited when the molecule absorbs a quantum of energy, E, corresponding to the vibration’s frequency, ?, according to the relation E = h? (where h is Planck’s constant). A fundamental vibration is excited when one such quantum of energy is absorbed by the molecule in its ground state. This patented technology allows less compounds to be used while increasing the effectiveness of Escozine™’s main ingredients.
Why is QNTA destined for GREATNESS?
THE small MOLECULE:
Why Small Molecules Are Still a Big Deal
Though large molecules and advanced therapies currently dominate headlines, small molecules remain of great significance for the industry – and patients
In 2018, major news included Abbvie’s Humira, a monoclonal antibody (mAb) approved for the treatment of arthritis and a range of diseases in the inflammation and immunology space, leading the pack of global highest-revenue drugs with sales of around $20 billion. In addition, innovative cell and gene therapies seem ready to revolutionize treatment for diseases from sickle-cell anemia to inherited genetic forms of blindness; the FDA expects to approve 10–20 cell and gene therapy products a year by 2025.
But scratch beneath the surface and you’ll see that biologics are not the only big players in the pharma space. Small molecules continue to play a significant role in the development of innovative treatments that benefit the lives of patients around the world. Specialty medicines are increasingly driving global pharma growth, especially in developed markets, with approximately half of specialty sales attributable to small molecule applications.
The continuing role of small molecules is also visible in recent approval trends and the current pipeline. In 2018, the FDA approved 59 new drugs, 71 percent of which were small molecules (29 percent were biologics). Specialty meds – which can be defined as high-cost, high-complexity medicines – are often associated with biologics and are highly visible in today’s pipeline, but small molecules represent an estimated 60 percent share versus large molecules. We are also seeing the impact of regulatory incentives with regards to orphan medicines specifically, with orphan designations playing an increasing role in both small and large molecule approvals, and accounting for more than half of US and European approvals in 2018.
QNTA has not seen a down trend like this since November of 2020:
It bottom out at 0.015 in intra-day trading on November 13, 2020.
5 days later it peaked to 0.09 on heavy trading before settling down and never going below 0.03 again until yesterday.
The stock price will recover. The question is how high will it move to?
There are many catalysts that could launched the stock price at any moment.
ESCOZINE:
It is on a road trip with down the FDA freeway with detours along the way. However QNTA will reach their intended destination which is IND application approval.
Detour
Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
Will there be more detours?
We will find out after QNTA submits the two addition toxicology studies.
We have people in our camp that should help to get us through the FDA approval process:
Agreed the Lonza situation.
Whether we contract with Lonza or a similar type company it doesn't matter WHO.
They will be needed for our necessary processes that needs to be done.
There are plenty of other companies they can provide for ENZC needs.
It was very encouraging to have Lonza possibly be involved however if they are not ENZC will find another company.
Here are the leading 10 companies in Cell Culture Market-
Merck & Company Incorporation
Irvine Scientific
GE Healthcare
Agilent Technologies
Thermo Fisher Scientific
Lonza
Corning Inc.
Sera Care Life Sciences Incorporation
Becton Dickinson
CellGenix GmbH
https://meticulousblog.org/top-10-companies-in-cell-culture-market/
Situation Awareness
Covid 19 Pandemic
Solution
Vaccines
The current vaccines work however better ones are needed and are being developed.
Other treatments
Here is were a major problem exist.
While some available treatments have been helpful there is nothing on the market that after contracting Covid, getting very ill and being hospitalized will shut the virus down.
We need treatments that will shut Covid down swiftly and effectively.
ENZC may have the solution and other companies will provide other solutions.
This is an "ALL HANDS ON DECK" situation.
There are faster ways to get drugs approved:
FDA Drug-Approval Process
A pharmaceutical company seeking FDA approval to sell a new prescription drug must complete a five-step process: discovery/concept, preclinical research, clinical research, FDA review and FDA post-market safety monitoring.
First, the company must conduct laboratory tests and try the drug on animals and then people to make sure it works and is safe.
Faster Approvals
In 1992, the U.S. passed the Prescription Drug User Fee Act (PDUFA), which allows the FDA to collect fees from companies to expedite the drug-approval process.
The act establishes two time frames for gaining approval: Standard Review and Priority Review.
The goal for standard review is to get a drug through the approval process in 10 months. This type of review is applied to a drug that offers little to no improvement over other therapies already on the market.
Priority review is a designation reserved for drugs that offer major advances in treatments or that provide treatment where none existed. The FDA aims to get a drug through the entire process in six months.
Further, the FDA has an accelerated approval pathway for some drugs used for serious and life-threatening illnesses that do not have adequate treatment. A limitation of the accelerated approval pathway is that it allows an NDA to be approved before means are available to fully measure the drug’s effectiveness — a step that would usually be required.
“Instead, less traditional measures called surrogate endpoints are used to evaluate effectiveness,” according to the FDA. “These are laboratory findings or signs that may not be a direct measurement of how a patient feels, functions, or survives, but are considered likely to predict benefit.”
Other avenues for faster review include breakthrough therapy or fast track designations. These avenues are used for drugs for serious conditions that demonstrate substantial improvement for treating the disease or fill an unmet medical need, respectively.
https://www.drugwatch.com/fda/approval-process/
Final Thoughts:
Desperate Times Call for Desperate Measures
Interesting fact about Desperate Times Call for Desperate Measures
ENZC has some promising solutions to solve some old and new diseases.
The process will take sometime and up to now the plan of action presented by the "Man in Charge", Charles Cotropia has moved along with some delays and setbacks.
https://enzolytics.com/company-news/
While we wait some light reading:
The Ups And Downs Of Biotechnology
Many traders dream of the day they can close out their positions and realize that one big gain. You've probably heard stories of novice traders who built up their trading accounts from mere thousands into millions.
Biotechnology is a sector where traders seek out these huge profits. For smart traders, this sector can present an incredible area of opportunity, but for those who are not willing to do their homework, it can be a train wreck waiting to happen. We'll use real-life examples to illustrate why this sector can be so appealing and what issues you should consider before putting your capital at risk.
KEY TAKEAWAYS
Investors are often tempted to look at the biotech sector for high return investments.
Investing in biotech, however, comes with risks, in part due to the fact that many of the products being researched or developed will never make it to market.
Biotech firms face many regulations as well, including from the FDA, which adds risk to the already volatile nature of developing new drugs.
The products produced in this sector are complex, where it would take the average investor significant time to understand the factors that affect the product’s chances of success.
Even large financial institutions tend to have a poor track record when it comes to predicting the performance of these companies.
The Big Win
Few sectors in the market see small single-product companies go from having tiny market capitalizations to having a worth over hundreds of millions practically overnight. The business of curing diseases can be a lucrative one, and investors will jump on the bandwagon for any stock that shows the promise of a big breakthrough.
As an example, as you can see in Figure 1, Novavax Inc. (NVAX) rose from a low of $0.74 in August 2005 to a high of $8.31 in March 2006. This is equal to an amazing 1,023% in seven short months. With gains like this, it is easy to see why so many are anxious to put money into this sector.
It's Not All Roses
You can't always put down $10,000 and come back in seven months to collect $102,300. Along with the opportunity to make huge gains comes the potential for some very devastating losses. Because most of the companies in this sector are relatively small, with no more than two or three products, news releases concerning their clinical trials and/or approval from the Food and Drug Administration (FDA) is one of the main factors deciding the direction of the company's stock. Companies in this sector can live and die by these announcements.
For example, investors of Threshold Pharmaceuticals (THLD) saw the price of their shares travel to a high of $16.98 in mid-April 2006 only to fall to a low of $3 in mid-May 2006. The major fall was attributed to the termination of the company's clinical trials upon the FDA's request. The 82% drop in roughly one month is a good example of what can happen when a company releases this type of bad news.
Even worse, notice in Figure 2 how the stock gaps down. This means that you have no chance of cutting losses once you've entered the trade. As an example, let's say that you bought the stock at around $15 and had a stop-loss order in for $13. In theory, the stop-loss should limit your loss to around $2 ($15 - $13). In volatile markets like this, however, you can't limit your loss. Your order will get filled at the open price of $3, not the $13 you wanted.
The Illusion of the Story
Many investors get wrapped up in the story of a small biotech firm and convince themselves that the company's product(s) will revolutionize its industry. Some investors even place money into these types of companies simply because they believe that complex products seem so impressive that they must work. It's not that impressive-sounding products can't be successful, but rather that it is extremely difficult for the average investor to get a handle on the probabilities of success for a drug.
For example, an investor researching Micromet Inc. (MITI) would have read on its Yahoo! Finance page that "its drug development platform is based on its BiTE technology, an antibody-based format that uses the cytotoxic potential of T-cells. The company's principal product candidates include Adecatumumab (MT201), a recombinant human monoclonal antibody.”
This might sound impressive, but do you have any idea what the company does? Perhaps those of you with doctorates in biology understand, but for the average person (or the average analyst), even understanding the product can be difficult. What this means is that you, the investor, are going to have to do a lot of homework to figure out exactly what the product is, what the company's strategic advances are and what risks are involved in the event that the product does not work.
Nobody Really Knows, Not Even the Big Guys
Since the companies in this sector can be very complicated, many traders will turn to large financial institutions for guidance. The buy and sell ratings made by these companies can be used as a tool to determine whether or not an investment decision should be made, but as you can see in Figure 3, they can be totally wrong.
In our first example, an investment bank issued a buy rating on Valentis Inc. (VLTS) on June 23, 2006. Eleven trading days later, the company released bad news about its drug and the stock fell a whopping 79% in one day. What did the firm that issued the buy rating do? They downgraded the stock to a hold rating. That makes you wonder how poorly a company has to perform to get a sell rating.
Another example of poor financial institution advice occurred on December 8, 2005, when a large investment bank issued a buy rating on DOV Pharmaceuticals Inc. (DOVP). At this point in time, the price was approximately $15, but as you can see in Figure 4, this changed within the next few months as the stock dropped off and hit a low of $2.71. On May 17, 2006, the investment bank came out and (again) issued a hold rating, but this rating was not much help to investors as the stock dropped again, to a new low of $1.85 a month later.
Conclusion
The biotechnology sector is very exciting and can be very rewarding for those who remain cautious and do their homework. However, it is easy to get caught up in the dream of 1,000% gains, or the intriguing stories of how certain companies' products will change the world.
It is important to realize that if you are aiming for huge gains in the biotech sector, you likely will encounter some bad trades that will leave you reeling at the reduction of the value of your account. We all know that investors make mistakes and, as shown above, even the big players can see their picks lose most of their value. If the big players can be completely wrong, so can you, so trade with caution and restraint. When it comes to investing in this high-risk sector, it may be wise to use only as much money as you can afford to lose.
https://www.investopedia.com/articles/trading/06/biotechsector.asp
There will always be runs however for QNTA to have a sustained upward movement it will take consistent solid results. They have built a great brand and have a solid footing in moving through the FDA bureaucracy.
QNTA built it and I'm hopeful results will come.
There is no reason for the stock price to increase significantly at this point in time.
QNTA has a lot of things going on and until we see some results such as increased product sales or FDA approvals, the stock price will suffer.
Spotlight on Microcap Fraud
The over-the-counter (OTC) market for securities, often referred to the microcap market, is designed for and comprised of companies with small amounts of assets and low stock prices. More than 10,000 companies have shares that trade on the OTC market’s two inter-dealer quotation systems: the OTC Bulletin Board (OTCBB) and OTC Markets Group, Inc. (f/k/a Pink Sheets). While companies that trade their stocks on major exchanges undergo a formal application process and must meet minimum listing standards, companies quoted on the OTCBB or the OTC Markets do not have to apply for listing or meet any minimum financial standards.
Watch out for these “Red Flags” when investing in Microcap Stock
SEC Trading Suspensions
Spam
Assets are Large but Revenues are Small
Odd Items in the Footnotes of Financial Statements
Unusual Auditing Issues
Insiders Own Large Amounts of Stock
What if I Want to Invest in Microcap Stocks?
To invest wisely and avoid investment scams, research each investment opportunity thoroughly and ask questions. These simple steps can make the difference between profits and losses:
Find out whether the company has registered its securities with the SEC or your state's securities regulators.
Make sure you understand the company's business and its products or services.
Read carefully the most recent reports the company has filed with the SEC and pay attention to the company's financial statements, particularly if they are not audited or not certified by an accountant.
If the company does not file reports with the SEC, be sure to ask your broker for what's called the "Rule 15c2-11 file" on the company.
Check out the people running the company with your state securities regulator, and find out if they've ever made money for investors before. Also ask whether the people running the company have had run-ins with the regulators or other investors.
Make sure the broker and his or her firm are registered with the SEC and licensed to do business in your state. And ask your state securities regulator whether the broker and the firm have ever been disciplined or have complaints against them.
QNTA IS NOT A SCAM
What is QNTA if it is not a scam?
Glad you asked.
QNTA is a company with very unique products due to a specific ingredient (scorpion venom).
Company Overview
Quanta, Inc. ("Quanta") is a cutting-edge technology platform whose patented, proprietary technology harnesses advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, anti-aging, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The company has the potential of two significant revenue streams.
1. The Aelia product line, Immunapen product line and other products.
2. Escozine for use to treat Covid-19 and in the future to treat cancer.
The first revenue stream is a tradition one. The more product sales the more potential for the stock to appreciate. The are many ways to get more sales and QNTA has executed some them and has plans to do more.
The second revenue stream is a quite a bit more complex, laborious and costly. However the rewards for getting this to the market would be priceless. Although QNTA is engaged with FDA to go from Pre-IND to IND
sooner than later, they still have to much work to do moving forward.
The second revenue stream has the most upside.
It is all about exposure.
Some may try it and like it and tell someone else about it who has no connection to TH.
This all takes time and we will see results or not through sales.
All stocks need liquidity so all traders day, short and long are welcome.
Results from the company will ultimately determine price movement.
MMs don't matter as the keep the stock moving based on supply and demand.
RGBP has some upcoming news that should be very favorable in the stock price movement.
Market Sentiment
Market sentiment refers to the psychology of market participants, individually and collectively. This is perhaps the most vexing category. Market sentiment is often subjective, biased, and obstinate. For example, you can make a solid judgment about a stock's future growth prospects, and the future may even confirm your projections, but in the meantime, the market may myopically dwell on a single piece of news that keeps the stock artificially high or low. And you can sometimes wait a long time in the hope that other investors will notice the fundamentals.
Market sentiment is being explored by the relatively new field of behavioral finance. It starts with the assumption that markets are apparently not efficient much of the time, and this inefficiency can be explained by psychology and other social science disciplines. The idea of applying social science to finance was fully legitimized when Daniel Kahneman, PhD, a psychologist, won the 2002 Nobel Memorial Prize in Economic Sciences (the first psychologist to do so). ? Many of the ideas in behavioral finance confirm observable suspicions: that investors tend to overemphasize data that come easily to mind; that many investors react with greater pain to losses than with pleasure to equivalent gains; and that investors tend to persist in a mistake.
Liquidity
Liquidity is an important and sometimes under-appreciated factor. It refers to how much interest from investors a specific stock attracts. Wal-Mart's stock, for example, is highly liquid and therefore highly responsive to material news; the average small-cap company is less so.3? Trading volume is not only a proxy for liquidity, but it is also a function of corporate communications (that is, the degree to which the company is getting attention from the investor community). Large-cap stocks have high liquidity—they are well followed and heavily transacted. Many small-cap stocks suffer from an almost permanent "liquidity discount" because they simply are not on investors' radar screens.
NEWS
While it is hard to quantify the impact of news or unexpected developments inside a company, industry or the global economy, you can't argue that it does influence investor sentiment. The political situation, negotiations between countries or companies, product breakthroughs, mergers and acquisitions and other unforeseen events can impact stocks and the stock market. Since securities trading happens across the world and markets and economies are interconnected, news in one country can impact investors in another, almost instantly.
The Bottom Line
Different types of investors depend on different factors. Short-term investors and traders tend to incorporate and may even prioritize technical factors. Long-term investors prioritize fundamentals and recognize that technical factors play an important role. Investors who believe strongly in fundamentals can reconcile themselves to technical forces with the following popular argument: technical factors and market sentiment often overwhelm the short run, but fundamentals will set the stock price in the long-run. In the meantime, we can expect more exciting developments in the area of behavioral finance, especially since traditional financial theories cannot seem to explain everything that happens in the market.
What is a runaway train?
RGBP's future
A runaway train is a type of railroad incident in which unattended rolling stock is accidentally allowed to roll onto the main line, a moving train loses enough braking power to be unable to stop in safety, or a train operates at unsafe speeds due to loss of operator control.
We are going to be ROLLING ROLLING ROLLLING!!!!
The Ups And Downs Of Biotechnology
Many traders dream of the day they can close out their positions and realize that one big gain. You've probably heard stories of novice traders who built up their trading accounts from mere thousands into millions.
Biotechnology is a sector where traders seek out these huge profits. For smart traders, this sector can present an incredible area of opportunity, but for those who are not willing to do their homework, it can be a train wreck waiting to happen. We'll use real-life examples to illustrate why this sector can be so appealing and what issues you should consider before putting your capital at risk.
KEY TAKEAWAYS
Investors are often tempted to look at the biotech sector for high return investments.
Investing in biotech, however, comes with risks, in part due to the fact that many of the products being researched or developed will never make it to market.
Biotech firms face many regulations as well, including from the FDA, which adds risk to the already volatile nature of developing new drugs.
The products produced in this sector are complex, where it would take the average investor significant time to understand the factors that affect the product’s chances of success.
Even large financial institutions tend to have a poor track record when it comes to predicting the performance of these companies.
The Big Win
Few sectors in the market see small single-product companies go from having tiny market capitalizations to having a worth over hundreds of millions practically overnight. The business of curing diseases can be a lucrative one, and investors will jump on the bandwagon for any stock that shows the promise of a big breakthrough.
As an example, as you can see in Figure 1, Novavax Inc. (NVAX) rose from a low of $0.74 in August 2005 to a high of $8.31 in March 2006. This is equal to an amazing 1,023% in seven short months. With gains like this, it is easy to see why so many are anxious to put money into this sector.
It's Not All Roses
You can't always put down $10,000 and come back in seven months to collect $102,300. Along with the opportunity to make huge gains comes the potential for some very devastating losses. Because most of the companies in this sector are relatively small, with no more than two or three products, news releases concerning their clinical trials and/or approval from the Food and Drug Administration (FDA) is one of the main factors deciding the direction of the company's stock. Companies in this sector can live and die by these announcements.
For example, investors of Threshold Pharmaceuticals (THLD) saw the price of their shares travel to a high of $16.98 in mid-April 2006 only to fall to a low of $3 in mid-May 2006. The major fall was attributed to the termination of the company's clinical trials upon the FDA's request. The 82% drop in roughly one month is a good example of what can happen when a company releases this type of bad news.
Even worse, notice in Figure 2 how the stock gaps down. This means that you have no chance of cutting losses once you've entered the trade. As an example, let's say that you bought the stock at around $15 and had a stop-loss order in for $13. In theory, the stop-loss should limit your loss to around $2 ($15 - $13). In volatile markets like this, however, you can't limit your loss. Your order will get filled at the open price of $3, not the $13 you wanted.
The Illusion of the Story
Many investors get wrapped up in the story of a small biotech firm and convince themselves that the company's product(s) will revolutionize its industry. Some investors even place money into these types of companies simply because they believe that complex products seem so impressive that they must work. It's not that impressive-sounding products can't be successful, but rather that it is extremely difficult for the average investor to get a handle on the probabilities of success for a drug.
For example, an investor researching Micromet Inc. (MITI) would have read on its Yahoo! Finance page that "its drug development platform is based on its BiTE technology, an antibody-based format that uses the cytotoxic potential of T-cells. The company's principal product candidates include Adecatumumab (MT201), a recombinant human monoclonal antibody.”
This might sound impressive, but do you have any idea what the company does? Perhaps those of you with doctorates in biology understand, but for the average person (or the average analyst), even understanding the product can be difficult. What this means is that you, the investor, are going to have to do a lot of homework to figure out exactly what the product is, what the company's strategic advances are and what risks are involved in the event that the product does not work.
Nobody Really Knows, Not Even the Big Guys
Since the companies in this sector can be very complicated, many traders will turn to large financial institutions for guidance. The buy and sell ratings made by these companies can be used as a tool to determine whether or not an investment decision should be made, but as you can see in Figure 3, they can be totally wrong.
In our first example, an investment bank issued a buy rating on Valentis Inc. (VLTS) on June 23, 2006. Eleven trading days later, the company released bad news about its drug and the stock fell a whopping 79% in one day. What did the firm that issued the buy rating do? They downgraded the stock to a hold rating. That makes you wonder how poorly a company has to perform to get a sell rating.
Another example of poor financial institution advice occurred on December 8, 2005, when a large investment bank issued a buy rating on DOV Pharmaceuticals Inc. (DOVP). At this point in time, the price was approximately $15, but as you can see in Figure 4, this changed within the next few months as the stock dropped off and hit a low of $2.71. On May 17, 2006, the investment bank came out and (again) issued a hold rating, but this rating was not much help to investors as the stock dropped again, to a new low of $1.85 a month later.
Conclusion
The biotechnology sector is very exciting and can be very rewarding for those who remain cautious and do their homework. However, it is easy to get caught up in the dream of 1,000% gains, or the intriguing stories of how certain companies' products will change the world.
It is important to realize that if you are aiming for huge gains in the biotech sector, you likely will encounter some bad trades that will leave you reeling at the reduction of the value of your account. We all know that investors make mistakes and, as shown above, even the big players can see their picks lose most of their value. If the big players can be completely wrong, so can you, so trade with caution and restraint. When it comes to investing in this high-risk sector, it may be wise to use only as much money as you can afford to lose.
https://www.investopedia.com/articles/trading/06/biotechsector.asp
11 Things to Know About Investing in Biotech Stocks
The biotech industry is super hot right now. Many of the companies out there have the potential to bring in huge returns, but the accompanying risks can be pretty steep. Besides that, not every biotech company and security are created equally. Before you start investing in the biotech industry, you should know a few characteristics of the sector and how to go about trading these tricky securities.
Takeaways:
Biotech stocks are high risk and high reward.
Researching the company is vital.
Active trading on biotech stocks is a must.
What Are Biotech Stocks?
The biotechnology industry uses living organisms to make commercial products, like pharmaceuticals and superior crops. In the stock world, biotech is often used as an umbrella term for any company that develops new drugs, whether the components are biological or not. This sector is constantly changing, growing, and developing as scientists discover new ways to treat illnesses and diseases, making biotechnology stocks a favorite investing choice for many traders.
Why Invest in Biotech Stocks?
People invest in biotech stocks for many reasons. First, many investors feel good about investing in a company that’s trying to help people live longer, healthier lives. Second, if the potential drug is successful, investors stand to make an extraordinary return on their investment. Third, the potential for strategic trades is high with biotech stock since any piece of news, positive or negative, from the company can send the price skyrocketing or falling only to change course the next day with the introduction of new information.
How to Invest in Biotech
Biotech stocks are historically volatile. Often, the value of the stock is all speculative and based on the promise of a new drug or treatment. Until the drug proves viable, receives FDA approval, and hits the market, investing is a big gamble. However, stock prices for these companies are often very low right up until news breaks. If you do your research and get in early, you can make a tremendous amount of money in this sector. Follow these steps to vet any biotech investment you’re considering.
1. Determine the sector
As mentioned, ‘biotech’ can be used as an umbrella term for any pharmaceutical. If you want to invest in a true biotech company, one that works exclusively with biological material, you need to learn about what the company does rather than just looking at its designation.
2. Establish an acceptable risk
Know how much money you’re willing to risk if the stock goes south. Establishing this before you find a company you’re excited about will hopefully help you act judiciously when it’s time to actually pay out for shares rather than acting on impulse and emotion.
3. Know the downsides
Biotech is risky. Even the ‘safe’ bets carry risk. Keep these common disadvantages of biotech investments in mind:
Clinical trial failure: If the drug fails in clinical trials, the company has to essentially start the scientific process over, which can take an enormous amount of time and send its share price spiraling.
Approval delays: Regulatory approval can take a long time. Even if a drug does well in trial, until it comes to market, the stock value might plateau or drop.
Commercialization setbacks: With all approval in place, the company still has to get the drug to market and hope it sells.
Competition or patent problems: Sometimes, while waiting on steps like trials and approval, competitors will beat the company to market or the patent on the drug might run out. Either of these scenarios can damage the share value.
4. Assess the company’s history
Learn about the company. See how quickly they’ve gotten other drugs to market and whether or not those drugs have good commercial sales. Biotech companies pop up all the time with no history to review. These investments are particularly risky, but also offer some of the highest potential payouts if they’re successful.
5. Keep your portfolio diversified
Avoid putting too much of your money into the biotech sector. Keep your portfolio diversified in case your investment doesn’t pan out. Greed can lead to devastation.
6. Check-in regularly
Biotech stocks are not investments you can purchase and sit on for years. Keep track of price, volume, and news from the company to see if you should invest in more stock, part with the shares you have before losing money, or sell at a profit.
Tips for Investing in Bio Stocks
Use these 11 tips to help you find great potential investments in the biotech industry and make data-driven, research-based trading decisions.
Know Where the Company is in the Process
It might cost slightly more to get in when a company is out of the clinical trial stage of product development, but it could potentially save you from losing a lot of money if they don’t even make it that far in the process. It’s important to know where the company is in development before buying in.
Consider Risk
Know the risk the company presents. You’ll want to assess history, stage of development, pipeline, partners, cash-on-hand to debt and ‘potential’ cash, and the company’s leadership and reputation. If you feel uneasy about more than two or three of these factors, it might not be the best risk level for you.
Look for Companies With Multiple Plans
It’s tempting to put all your money into a company that’s focused on a single product and putting all its money and resources into it. However, it’s often a safer investing move to find a company that has several ongoing projects in case its front runner fails.
See Who Is Investing
Look and see who’s investing in the company. Often, big-name companies, either in the industry or even some from outside, will put money into the biotech firm’s research and development. You want a solid amount of funding from reputable sources.
Find Companies With Partners
Support, support, support. Any company at risk of going under should their one drug lose viability is not a great investment. Look for companies with partners who can continue project funding should the front-running drug fail at some stage in the development process.
Know the Cash to Biobucks Ratio
The biotech industry uses the term ‘biobucks’ as a synonym for potential payouts should their drug make it to market. Many biotech firms calculate their support using upfront cash and biobucks. If you see an announcement that a biotech firm just got a huge deal, look at the fine print to see how much of that is cash now and how much is conditional.
Look Past the Press Releases
Reading the news about the company and its development progress isn’t enough. You need to dig into its research and see how frequently researchers are performing clinical trials compared to how often you see ‘news’ about the company. You want actual progress, not just the illusion of progress.
Read the Reports
Take the time to review the actual reports on clinical trials. It’s easy enough to spin findings positively for a layman’s press release. It’s harder to disguise facts in a scientific study. You could get ahead of a bad move by checking the real numbers.
Look at the Competition
Multiple companies competing over the same treatment can help boost stock prices, but if you side with the losing company, you could be out a lot of money. Consider investing in companies that don’t have any immediate competition.
Consider the Leadership
Look at the leaders of the company. Learn about their history, management style, risk tolerance, and other characteristics. You want to invest in a company with trustworthy and capable leaders.
Avoid Emotional Investing
If you find yourself getting super excited about a potential investment and itching to hit that buy button without any research, take a minute to calm down. Emotional investing without the facts can lead to disaster in the biotech industry.
https://ragingbull.com/biotech-stocks/11-things-to-know-about-investing-in-biotech-stocks/
I don't believe QNTA is for sale so the below information is just to share some tidbits of the landscape we are facing to get our product to the marketplace.
3 SIGNS THAT YOUR BIOTECH IS ABOUT TO BE ACQUIRED
More than $100,000,000,000 were spent on pharmaceutical M&A in the first six months of 2018. Here is how to tell if your biotech is a payday waiting to happen…
The California Gold Rush has begun anew… but this time the gold comes in the form of test tubes, published papers and CNBC interviews. Over the last six months, small (and not so small) biotechnology companies have been gobbled up by famished Big Pharma buyers at an accelerating pace. Common “take out premiums” have been 40, 60, even 80% of a company’s going share price. Many experts believe that we are only in the early moments of a biotechnology M&A party that could make shareholders rich swiftly. Identifying and buying such biotechs with an eye towards a quick cashout would be great work if you can get it… and you can get it if you try.
1) Your Company is Down, But Not Out.
If you are a frequent reader of this blog, then you know that one of my core beliefs is that share prices assigned by Wall Street know-it-alls are often insane. Despite hoards of MBA’s armed with hundreds of loaded spreadsheets, often times valuations are simply driven by assumptions. And assumptions can boil down to simple human factors like mood.
That’s right, the sum value of hundreds of scientists’ blood, sweat and tears can boil down to the whims of Wall Street. Which therapies are in vogue at the moment? Which technologies sound sexy and fresh? Which kids at the biotechnology party are this week’s cool kids?
Such was the case with Celgene ($CELG). Founded way back in 1986, Celgene had been one of Wall Street’s original Billionaire Biotech Babies. It grew from a scrappy biotech start up to a giant provider of key cancer drugs. Celgene’s most important drug was a blockbuster for blood cancer known as Revlimid. Between 2010 and 2017, the company’s share price rocketed from $25 to $139.
But somewhere along the way, Wall Street’s euphoria around Revlimid gave way to fear about patent expirations, new competition, and a lackluster pipeline. Poor $CELG watched it’s share price plummet from $139 all the way down to $60 in less than 18 months. Was the former Belle of the Biotech Ball suddenly losing money? Was revenue in a free fall??? Not at all!!! In fact, 2018 revenue was only slightly down from it’s 2017 peak, while the company continued to churn out billions of dollars in profit.
Celgene tried everything. New and exciting collaborations with well known biotech dynamos. Promising acquisitions of smaller companies with loaded pipelines. A media friendly policy that sought to engage with Wall Street critics. No matter how they tried, poor $CELG was just viewed as a “has been” by the Wall Street fast money crowd.
This made them very appealing for Bristol Myers Squibb. $BMY hasn’t been sexy in a long time. They simply grind out predictable cash flows and profits, year after year, decade after decade. $BMY’s investors are a totally different breed than typical biotech investors; a well supported dividend and modest, predictable price appreciation are what pensions and widows look for in their $BMY holdings. A new source of steady cash flow with a depressed stock price looked like an opportunity in this context. Now one of Wall Street’s biggest pharmaceutical marriages ever has been arranged. Celgene will no longer be at the mercy of Wall Street temper tantrums, and Bristol Myers Squibb will get its hands on some lightly used assets at a bargain price. If you bought $CELG at $138 two years ago, it’s an unhappy ending to your story. If you bought at $60 just a few months ago, you are about to make out like a bandit. Take note.
2) Your Science is Fabulous. Your Bank Account isn’t.
You would think that if you could laboriously develop a better medicine to meet an unmet need, and backup that new medicine with strong scientific proof, that the end product would fly off the shelf. There are still so many unmet needs in the medical community, surely society would swiftly embrace anything that would help suffering patients, right? Ummm. Not so much.
In the tortuous journey from concept to reality, medicines actually face two massive barriers. Only the first is purely scientific. The other, sometimes larger, hurdle for a new medicine to gain widespread adoption is an American Medical System that often feels like an episode of the Twilight Zone. In order for an expensive new medicine to gain traction, it must gain acceptance from a mix of public and private insurers. If its a novel method of action, distributors or hospitals may struggle to accommodate a new way of administering or storing the medicine. Finally, many physicians are risk averse, poorly incentivized, or simply “stuck in their ways” and may need very substantial convincing or coaching. All of this costs money. Lots and lots of money. It’s not uncommon for an investment of hundreds of millions or even a billion dollars to be necessary to launch a new drug. That is AFTER the science has been proven through rigorous clinical trials.
Today’s M&A landscape exists largely because it allows different kinds of people to form different kinds or organizations that excel at certain niche tasks. There are few organizations on earth with as much financial and political muscle as a major Big Pharma concern. But these corporate giants are often poor at scientific innovation for cultural reasons. Young upstart biotechs, often founded by starry eyed scientists looking to change the world, can be shockingly inventive in the science lab. But they simply don’t have the mental or financial resources to navigate the treacherous jungle of red tape that stands between medical breakthroughs and patients. Thus, M&A.
There are a few tell tale signs you can look for if you want to mine for M&A gold in this vein. First, look for biotechs with agents that have already passed through stage one and stage two studies. These studies are typically just designed to prove the basic viability of a concept. But they can still cost mountains of cash to complete.
When you hear about a smallish company that has attained promising phase 2, or even phase 3 results on a new molecule, immediately go to Etrade and find out how much cash they have left on their books. This can be found by quickly checking the company’s balance sheet and cash flow. If you are semi literate in accounting, the question is, “How much cash per quarter is this company burning?” For example, if they are burning approximately $25 million per quarter, they have a good stage two data, but only $75 million left in the bank, then you know that something needs to happen. Companies with hard won good data don’t want new agents to wind up in the garbage can just because they ran out of cash at the wrong moment. If you are not accounting literate, do as much reading on the company as possible, or check an analyst’s report. “Cash Burn” is a common metric, and most analysts will point out how long a company can operate without some kind of capital raise.
Big Pharma execs really like to minimize risk. That is typically why they have built careers with big, established companies. By allowing scrappy bands of scientists to do the most risky lab work on their own, they are able to swoop in when the scientific risk is more or less controlled. Big Pharma eats red tape for breakfast. When the science is proven, playtime is over and the “adults” are ready to take over. If you are lucky enough, or smart enough, to time your biotech investments just right, you can reap the rewards of these transactions.
3) Your Controlling Shareholder is at the End of Her Career. Or the Beginning of Her Career.
The funny thing about the world of biotech is that companies can be valued at a $ 1 Billion or more without selling a single product. All of the value is in the assets that the company has developed, which will theoretically lead to boku bucks one day. Theoretically.
So you can understand why a 67 year old scientist founder might be tempted to take a giant payout from Big Pharma and move to Boca Raton. Let’s consider the math. It’s not unusual for a biotech with a promising phase two product and good data to be valued as high as $500,000,000. Now, at this point the founding team has probably been laboring in obscurity for years, and they likely have taken on investors to fund their expensive biotech dreams. Its rare for a founder to retain majority control throughout the product development process because it’s just so expensive. However, the founder, or founding group, could retain 5 or even 10% of the company’s shares. That may well make him or her the largest, most influential shareholder. So, if Pfizer offers to buy that company for $500,000,000, some ageing nerd with a PhD may well be walking away with $50,000,000. That is. A. Lot. Of. Money.
By the way, few scientist founders achieve those kinds of take out offers without suffering through a long career of disappointments and setbacks. They may well understand that the current $500 million valuation that the market is assigning to their still unproven company could vanish with one bad trial result. If they have been burned once, twice, or three times in their younger years, sometimes they know a good deal when they see it. If you chose to take a biotech ride with an experienced, elder founder, you may well have the chance to ride off into the sunset together.
Another scientist founder who is likely to sell his or her company is a very young, inexperienced entrepreneur. This may seem counterintuitive. Why would a young person, with many decades ahead of him, not try to “go all the way” and grow the company to maturity? Aren’t young people supposed to have more balls than brains?
Sometimes a young founder will insist on “going all the way.” But they may well have certain naive qualities that allow them to be duped by more sophisticated corporate deal makers. The pitch might go like this:
“Why Dr. X, as well as your doing due to your astounding entrepreneurial skills, imagine how well you could do if you teamed up with Pfizer? What could you do with our unlimited resources? No more worrying about paying your bills, just unlimited scientific progress!!! Why, with our resources, your could finally change the world!!”
Believe it or not, a lot of young people have bought into these kinds of pitches. But it rarely works out the way the young entrepreneur envisions. Ask everyone who ever sold a company to Facebook. Massive mega corporations tend to be poor places for formerly independent entrepreneurs to thrive. But don’t worry, Dr X still walks away with his $50,000,000. If you identify the right dreamer, with the right technology, at the right time, you can walk away rich too.
M&A will continue to thrive in the world of healthcare investing because it works. Most of the pills in your medicine cabinet today started out as the brainchild of a scientist founder. The pills wound up in your cabinet because Big Pharma doesn’t often take “no” for an answer. Along this journey of discovery and commercialization, a lot of people made a lot of money. Why not you too?
https://www.sickeconomics.com/2019/01/25/3-signs-biotech-acquired/
BrainChip Receives Akida Chips from Socionext America
ALISO VIEJO, Calif.--(BUSINESS WIRE)--BrainChip Holdings Ltd (ASX: BRN), (OTCQX: BRCHF), a leading provider of ultra-low power high performance artificial intelligence technology, today announced it has received the first batch of Akida™ chips from its manufacturing run from Socionext America (SNA).
“These production units from Socionext and TSMC will be part of pioneering devices that are at the forefront of Beneficial AI, as we approach production shipments of boards and systems in Q4 2021.”
The chips were manufactured at Taiwan Semiconductor Manufacturing Company (TSMC) from a production mask set provided in May 2021. This mask set follows the successful production of engineering samples from the Company’s Multi-Project Wafers (MPW), received in August of 2020, and the subsequent delivery of evaluation boards.
SNA supported all assembly and test operations for the Akida devices, including a review of the TSMC Process Control Monitoring (PCM) data, assembly, device electrical testing, and simulation correlation.
These Akida devices will support BrainChip’s Early Access Program (EAP) customers, future customers with whom the Company has engaged using the BrainChip software development environment MetaTF and others which have existing Convolutional Neural Networks (CNNs) and seek performance improvements in terms of power consumption, design flexibility, and true learning at the edge.
“As a company our goal has been to put our chips and IP into the hands of customers and partners so they in turn can transform edge AI for implementations like home automation, industrial IoT, security and cybersecurity, autonomous vehicles, medical devices, and leveraging sensor technology for objects, sound, odor, taste, vibration and more,” said Rob Telson, BrainChip vice president of sales and marketing. “These production units from Socionext and TSMC will be part of pioneering devices that are at the forefront of Beneficial AI, as we approach production shipments of boards and systems in Q4 2021.”
BrainChip brings AI to the edge in a way that existing technologies are not capable. The Akida processor is ultra-low power with high performance supporting the growth of edge AI technology by using a neuromorphic architecture, a type of artificial intelligence that is inspired by the biology of the human brain.
Akida is currently available now to be licensed as IP as well as available for orders for production release in silicon. Its focus is on low power and high-performance enabling sensory processing, for applications in Beneficial AI as well as applications including Smart Healthcare, Smart Cities, Smart Transportation and Smart Home.
About BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF)
BrainChip is a global technology company that is producing a groundbreaking neuromorphic processor that brings artificial intelligence to the edge in a way that is beyond the capabilities of other products. The chip is high performance, small, ultra-low power and enables a wide array of edge capabilities that include on-chip training, learning and inference. The event-based neural network processor is inspired by the spiking nature of the human brain and is implemented in an industry standard digital process. By mimicking brain processing BrainChip has pioneered a processing architecture, called Akida™, which is both scalable and flexible to address the requirements in edge devices. At the edge, sensor inputs are analyzed at the point of acquisition rather than through transmission via the cloud to a data center. Akida is designed to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications. The reduction in system latency provides faster response and a more power efficient system that can reduce the large carbon footprint of data centers.
Additional information is available at https://www.brainchipinc.com
Follow BrainChip on Twitter: https://www.twitter.com/BrainChip_inc
Follow BrainChip on LinkedIn: https://www.linkedin.com/company/7792006
Follow BrainChip on YouTube: BrainChipInc
Contacts
JPR Communications
Mark Smith, 818-398-1424
marks@jprcom.com
BrainChip Holdings (ASX:BRN) issues call notice to LDA Capital
16 August 2021 09:30 (AEST)
Artificial intelligence (AI) processor technology company BrainChip Holdings (BRN) issues a capital call notice to LDA Capital for over 8.7 million shares
Last year, the global tech company entered a put option agreement with LDA to receive up to $29 million in equity capital
BrainChip will use the funds to support the commercialisation of its Akida technology
Additionally, the company is committed to draw down a minimum of $9.2 million by the end of October
BrainChip is down 1.87 per cent and is trading at 52.5 cents per share at 11:18 am AEST
BrainChip Holdings (BRN) has issued a capital call notice to LDA Capital for over 8.7 million shares.
A capital call is a legal right of an investment firm or an insurance firm to demand a portion of the money promised to it by an investor.
Last year, the global tech company entered a put option agreement with LDA to receive up to $29 million in equity capital.
BrainChip will use the funds to support the commercialisation of its Akida technology.
Additionally, the company is committed to draw down a minimum of $9.2 million by the end of October.
Founder and CEO, Peter van der Made, said the funds would be used to strengthen its balance sheet to support Akida technology.
"Proceeds will also be used to strengthen the sales and marketing team in anticipation of the launch of Akida later this year, as well as increased focus on customer engagement and investor relations activities in Australia, the US and Europe," he said.
BrainChip was down 1.87 per cent and is trading at 52.5 cents per share at 11:18 am AEST.
5 days for a 10Q.
ENZC just need to keep doing their development and production.
They may be called upon to speed things up as much as possible of course with a blank check in hand.
Situation Awareness
Covid 19 Pandemic
Solution
Vaccines
The current vaccines work however better ones are needed and are being developed.
Other treatments
Here is were a major problem exist.
While some available treatments have been helpful there is nothing on the market that after contracting Covid, getting very ill and being hospitalized will shut the virus down.
We need treatments that will shut Covid down swiftly and effectively.
QNTA may have the solution and other companies will provide other solutions.
This is an "ALL HANDS ON DECK" situation.
There are faster ways to get drugs approved:
FDA Drug-Approval Process
A pharmaceutical company seeking FDA approval to sell a new prescription drug must complete a five-step process: discovery/concept, preclinical research, clinical research, FDA review and FDA post-market safety monitoring.
First, the company must conduct laboratory tests and try the drug on animals and then people to make sure it works and is safe.
Faster Approvals
In 1992, the U.S. passed the Prescription Drug User Fee Act (PDUFA), which allows the FDA to collect fees from companies to expedite the drug-approval process.
The act establishes two time frames for gaining approval: Standard Review and Priority Review.
The goal for standard review is to get a drug through the approval process in 10 months. This type of review is applied to a drug that offers little to no improvement over other therapies already on the market.
Priority review is a designation reserved for drugs that offer major advances in treatments or that provide treatment where none existed. The FDA aims to get a drug through the entire process in six months.
Further, the FDA has an accelerated approval pathway for some drugs used for serious and life-threatening illnesses that do not have adequate treatment. A limitation of the accelerated approval pathway is that it allows an NDA to be approved before means are available to fully measure the drug’s effectiveness — a step that would usually be required.
“Instead, less traditional measures called surrogate endpoints are used to evaluate effectiveness,” according to the FDA. “These are laboratory findings or signs that may not be a direct measurement of how a patient feels, functions, or survives, but are considered likely to predict benefit.”
Other avenues for faster review include breakthrough therapy or fast track designations. These avenues are used for drugs for serious conditions that demonstrate substantial improvement for treating the disease or fill an unmet medical need, respectively.
https://www.drugwatch.com/fda/approval-process/
Final Thoughts:
Desperate Times Call for Desperate Measures
Interesting fact about Desperate Times Call for Desperate Measures
Situation Awareness
Covid 19 Pandemic
Solution
Vaccines
The current vaccines work however better ones are needed and are being developed.
Other treatments
Here is were a major problem exist.
While some available treatments have been helpful there is nothing on the market that after contracting Covid, getting very ill and being hospitalized will shut the virus down.
We need treatments that will shut Covid down swiftly and effectively.
ENZC may have the solution and other companies will provide other solutions.
This is an "ALL HANDS ON DECK" situation.
There are faster ways to get drugs approved:
FDA Drug-Approval Process
A pharmaceutical company seeking FDA approval to sell a new prescription drug must complete a five-step process: discovery/concept, preclinical research, clinical research, FDA review and FDA post-market safety monitoring.
First, the company must conduct laboratory tests and try the drug on animals and then people to make sure it works and is safe.
Faster Approvals
In 1992, the U.S. passed the Prescription Drug User Fee Act (PDUFA), which allows the FDA to collect fees from companies to expedite the drug-approval process.
The act establishes two time frames for gaining approval: Standard Review and Priority Review.
The goal for standard review is to get a drug through the approval process in 10 months. This type of review is applied to a drug that offers little to no improvement over other therapies already on the market.
Priority review is a designation reserved for drugs that offer major advances in treatments or that provide treatment where none existed. The FDA aims to get a drug through the entire process in six months.
Further, the FDA has an accelerated approval pathway for some drugs used for serious and life-threatening illnesses that do not have adequate treatment. A limitation of the accelerated approval pathway is that it allows an NDA to be approved before means are available to fully measure the drug’s effectiveness — a step that would usually be required.
“Instead, less traditional measures called surrogate endpoints are used to evaluate effectiveness,” according to the FDA. “These are laboratory findings or signs that may not be a direct measurement of how a patient feels, functions, or survives, but are considered likely to predict benefit.”
Other avenues for faster review include breakthrough therapy or fast track designations. These avenues are used for drugs for serious conditions that demonstrate substantial improvement for treating the disease or fill an unmet medical need, respectively.
https://www.drugwatch.com/fda/approval-process/
Final Thoughts:
Desperate Times Call for Desperate Measures
Interesting fact about Desperate Times Call for Desperate Measures
Update to the investors webpage?
https://brainchipinc.com/investors/
Reminds me of "Run Forest Run"
The best is yet to come.
The Forest run started slow and keep picking up and picking up and then BAM.
Then the BAM BAM.
Then the BOOM!!!
Yes many companies make fully human mAbs however up to present time none have been highly successful.
What ENZC has will be successful against Covid-19 and any variants it produces and "NO VIRUS ESCAPE".
Why with so many "other companies" introducing monoclonal antibodies is ENZC needed?
CEOCFO: What are you looking at regarding COVID?
Mr. Cotropia: We have produced an HIV monoclonal antibody that had been successfully tested in five international labs where it neutralized 95% of all strains against which it was tested. There are 6000 different strains of the HIV virus now known. We know that that our antibody is effective and we know the target site on the virus resulting in neutralization of the HIV virus. For an antibody to be effective it has to attack a neutralizable site on the virus that is always there, does not mutate from strain to strain. Knowing the binding site of our HIV monoclonal antibody, and then examining the CoronaVirus amino acid sequence, a correlation in the structures has been identified by our CSO, Dr. Joseph Cotropia, between the CoronaVirus and the HIV virus. With knowledge of these homologous viral structures, monoclonal antibodies will be created that target the corresponding “Achilles Heel” site on the CoronaVirus, an expected conserved immutable and neutralizable site on the virus. Additionally, using artificial intelligence, we will examine the numerous different strains of the virus to identify other conserved sites and produce additional monoclonal antibody targeting them. This is for the purpose of producing a “collection” or “cocktail” of antibodies for therapeutic use. We recognize that there are now known over 16,000 different variations or strains of the CoronaVirus, each slightly different due to mutation. A successful monoclonal antibody “cocktail” therapy must include multiple antibodies that specifically target several immutable sites and which results in neutralization.
Also, as all experts in the field of monoclonal antibodies agree, including Dr. Anthony Fauci, head of the NIAID/NIH, to have an effective therapy, we must have multiple monoclonal antibodies that target various sites on the virus - and in fact, even President Trump was given a cocktail of two. Therefore, it is imperative to identify conserved neutralizing binding sites on the CoronaVirus, and create multiple monoclonal antibodies that target these critical neutralizable and immutable structures. It is like finding a needle in a haystack and retrieving the needle; you must identify the immutable sites on the virus and then create and characterize fully human monoclonal antibodies that target those sites. process described here will be our focus and for the reason that success has already been achieved with regard to the production of broadly neutralizing antibodies directed against the HIV virus, we expect success will likewise be achieved in production of broadly neutralizing human monoclonal antibodies directed against the CoronaVirus.
What happened to Eli Lilly's Coronavirus monoclonal antibody?
FAILURE!!!
On Nov. 9, 2020, based on the totality of scientific evidence available at the time, the FDA issued an EUA to Eli Lilly and Co. authorizing the emergency use of bamlanivimab alone for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Importantly, although the FDA is now revoking this EUA, alternative monoclonal antibody therapies remain available under EUA, including REGEN-COV (casirivimab and imdevimab, administered together), and bamlanivimab and etesevimab, administered together, for the same uses as previously authorized for bamlanivimab alone. The FDA believes that these alternative monoclonal antibody therapies remain appropriate to treat patients with COVID-19 when used in accordance with the authorized labeling based on information available at this time.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab
Then the HAMMER came down:
COMPLETE FAILURE!!!
The Assistant Secretary for Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services are committed to ensuring timely and transparent communication regarding the COVID-19 monoclonal antibody treatments currently authorized for emergency use in certain patients with COVID-19.
Today, we are informing you that ASPR is immediately pausing all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility for use under EUA 094) on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies, as described below, and not use bamlanivimab and etesevimab administered together at this time.
https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/bamlanivimab-etesevimab-distribution-pause.aspx
So what is Eli Lilly up to now?
Eli Lilly has begun clinical development of an anti-SARS-CoV-2 antibody designed to work against all currently known circulating variants of concern. The action comes weeks after the FDA revoked the single use emergency authorization of Lilly’s first COVID-19 antibody due to the rise of variants.
What about UNKNOWN or FUTURE variants Eli Lilly?
Researchers have shown COVID-19 antibodies including Lilly’s bamlanivimab are less effective against variants of concern such as B.1.351 than the original SARS-CoV-2 virus when given as monotherapies. The research, coupled to the emergence of variants of concern as the dominant causes of COVID-19 in parts of the world, has led to reassessments of the use of antibodies as single agents.
AbCellera, which worked with Lilly on bamlanivimab, responded to variants by searching the blood of a patient who recovered from COVID-19 for an antibody that is effective against them. The result is LY-CoV1404, an antibody that binds to a conserved part of the receptor-binding domain.
https://www.fiercebiotech.com/biotech/lilly-takes-variant-busting-covid-19-antibody-into-clinic
What about the other Coronavirus monoclonal antibody from AstraZeneca?
FAILURE!!!
AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms.
The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.
The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.
AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.
https://www.cnbc.com/2021/06/15/astra-antibody-cocktail-fails-to-prevent-covid-19-symptoms-in-trial.html
ENZC is going through the processes to produce monoclonal antibodies that will be safe, effective against ALL variants known and UNKNOWN.
There is always a possibility that ENZC may be called upon to hurry things up of course with a BLANK CHECK.
It is a bit more than a classic penny set-up.
The thought of Scorpion Venom being a solution to different medical maladies is uncommon, unbelievable, exceptional, unique, unknown, unprecedented, unusual, new, novel, normal and obscure or anyway onemay want to describe the situation.
The fact that science supports their research and the FDA has and IND application pending suggests something much much GREATER.
Ethereum Overtakes PayPal, Bank Of America, Nike, And Pfizer In Market Cap As Proponents Set Their Eyes On Bitcoin
Ethereum Overtakes PayPal, Bank Of America, Nike, And Pfizer In Market Cap As Proponents Set Their Eyes On Bitcoin
Ethereum (CRYPTO: ETH) continues its astronomical rise as favorable fundamentals motivate buyers to pile up and drive demand for the coin, overtaking major publicly traded firms as proponents talk about it potentially overtaking top cryptocurrency Bitcoin (CRYPTO: BTC).
What Happened: According to crypto and stock market cap tracking service Infinite Market Cap, Ethereum's market cap — standing at over $329 billion at press time— is now higher than Paypal Holdings Inc (NASDAQ: PYPL), Bank of America Corp (NYSE: BAC), Adobe Inc.'s (NASDAQ:ADBE), Nike Inc.'s (NYSE:NKE), Comcast Corporation's (NASDAQ:CMCSA), Pfitzer's (NYSE:PFE), and Toyota (NYSE:TM).
While overtaking blue-chip companies is a notable accomplishment on its own, Ethereum proponents now hope to take on much harder to tackle objectives.
What It Means: Ethereum proponents are talking about the "flippening" — a hypothetical situation in which Ether's market cap surpasses that of Bitcoin.
CEO of a crypto finance platform Celsius Network Alex Mashinsky, recently argued that this event is already happening.
He noted that recently the users of his platform started holding more Ether than Bitcoin.
The firm manages a notable $17 billion, and the top asset they hold is Ether.
Pantera Capital CEO Dan Morehead recently said that fundamentals are likely to push Ether higher until it eventually overtakes Bitcoin as the top cryptocurrency.
According to him, Ethereum has a lower environmental impact, potential applications, and protocol upgrades, with one happening today.
For instance, he cited the Ethereum Improvement Proposal (EIP) 1559, an upgrade that activated on the coin's blockchain today and will lead to thousands of Ethers being burned (destroyed forever) each day, countering the coin's inflation.
The same update will also improve Ethereum's usability by making transaction fees more predictable and increasing transaction efficiency by implementing variable block size, allowing for a single block to process double the number of transactions that was previously possible.
EIP-1559's impact is expected to increase in the future when Ethereum finally transitions to a Proof-of-Stake (PoS) algorithm from its current Proof-of-Work (PoW) implementation.
The reason is that operating a PoS network is much more energy-efficient than operating one that uses PoW, allowing developers to reduce new coin issuance while still subsidizing network maintenance enough to keep it secure.
PoS networks not needing energy-intensive "mining" operations also means that it is widely viewed as a much greener option, which makes them a much more welcome investment option among institutional investors.
One example of this working against Bitcoin is Tesla Inc's (NASDAQ:TSLA) decision to stop accepting it over environmental concerns, with many speculating that the real reason was actually shareholder pressure.
Morehead said that he expects "people who want to store wealth, doing it in (Ether) rather than just Bitcoin."
How Are Ether And Bitcoin Different?
Bitcoin is intended to be money that cannot be controlled by any central government or financial institution that was created as a reaction to the monetary policy and governments playing a major role in 2008's financial crisis.
Ethereum, on the other hand, was first marketed as the "world computer" and was meant to allow to automate finance and financial organizations through programmable money through so-called "smart contracts."
Thus, those two assets are significantly different in their stated purpose and features, Bitcoin being slowly evolving but more stable and Ethereum being more fast-paced in its update schedule, gaining new features more often, which in turn makes it potentially less secure.
Before judging Bitcoin for its slow-paced evolution, we need to understand that adding any new code to any software is an opportunity for bugs and cybersecurity vulnerabilities to make their way into the system.
Bitcoin is much more focused on being as decentralized and secure as possible, making the network a safer bet if what you are after is reliability.
It may look like a dinosaur eating lots of coal, with low transaction throughput and with much more limited programmability, but this is the cost of its security and reliability.
Bitcoin was believed by many to be the better long-term investment option when compared to Ethereum's, due to its hardcoded limit of 21 million of the coins ever available to mine, while Ethereum has no hard limit, an inflation rate exceeding 4%, and circulating supply just under 117 million ETH as of press time. Still, with the introduction of EIP-1559, the long-term views of some experts shifted in Ether's favor.
When it comes to real-world utility — important for assigning a value floor for assets beyond their speculative appeal — both the coins delivered only part of what they were meant to achieve, but both could still deliver all of their original promises.
Bitcoin was meant to become the world's currency beyond any government's or bank's control, and while it managed to keep its independence from any centralized entity, it failed in becoming a practical currency as of yet.
What Else: Scalability may be the biggest obstacle: Bitcoin is currently able to process only between 3.3 and 7 transactions per second, with transactions usually taking hours and costing tens of dollars in fees.
Bitcoin's current transaction processing capabilities are a far cry from Visa's 1,700 instantaneous transactions per second and the even higher transaction processing speed that would be needed for an asset to become the world's currency.
Still, software developers are making increasingly practical and secure ways to spend Bitcoin instantly, with nearly no fees and scalability limits with developments such as "lightning network."
Similarly, Ethereum promised to deliver a decentralized network that would serve as the "internet of money" and allow the world's organization to operate on it.
But after the network started being used after spawning decentralized finance (DeFi), non-fungible tokens (NFTs), and other decentralized applications (DApps), it encountered the same problem as Bitcoin — with network strain, increased transactions became too costly and slow.
Also, Ethereum attracted developers trying to solve its scalability limitations and got its own scalability solutions such as Optimism, which already runs decentralized exchanges, or some even getting its own native currency Polygon (CRYPTO: MATIC).
That being said, neither of the two blockchains has yet delivered everything that they hoped to achieve despite such solutions.
Another thing that sets apart Ethereum and Bitcoin is their decentralization.
While you can easily run a full Bitcoin node on less than $100 worth of computer hardware, it is much more expensive to run an Ethereum full node.
According to Network statistics, Ethereum has a total of 4,551 synced network nodes, whereas Bitcoin has 12,666 nodes and advantage of 178%.
This is an important metric because full node operators are sentinels ensuring that miners, mining pools, and other network operators do not collude and lead to the blockchain actions against the set rules.
Since full nodes make networks more secure, a security-centric network, such as Bitcoin, prioritized getting as many nodes as possible by keeping it simple to ensure that full node network and hardware requirements are low and anyone can run a node.
Ethereum, on the other hand, prioritized features and created a much more feature-rich blockchain that can fix any issues at a later time.
This results in a network that has more features, but it had a critical vulnerability that could have broken it for two years until it was fixed in late May.
The Final Verdict
Which cryptocurrency is better? Well, it really depends on what you are looking for.
If you're after a dependable and secure network but lower, then Bitcoin is the obvious choice.
If you want all of the latest features, smart contracts, decentralized exchanges, and much more, then Ether is the choice among the two.
Which one is the better investment and store of value? This is a much harder question that really depends on the value that we assign to the features of both coins.
There's no clear-cut answer that is objectively true since — as with most things in life — it is just too complicated for there to be a simple answer.
https://www.benzinga.com/markets/cryptocurrency/21/08/22354662/ethereum-overtakes-paypal-bank-of-america-nike-and-pfizer-in-market-cap-as-proponents-set-
Enter your Ethereum mining hashrate, power consumption in watts, and costs.
Ethereum Mining Hashrate Tooltip for Ethereum Mining Hashrate MH/s
200,000.00
Power Consumption in Watts Tooltip for Power Consumption in Watts
1350.00
Electricity Costs in $ / kWh Tooltip for Electricity Costs in $ / kWh
0.10
Pool / Maintenance Fees
???
Mining Revenue
$12,071.86
Mining Fees
$0.00
Electricity Costs
$3.24
0.18717712 ETH
Ethereum mined per hour
4.49225091 ETH
Ethereum mined per day
$12,068.62
Ethereum mining profit per day
$84,480.34
Ethereum mining profit per week
$362,058.30
Ethereum mining profit per month
https://www.coinwarz.com/mining/ethereum/calculator?h=200000&p=1350.00&pc=0.10&pf=0.00&d=7693247930692871.00000000&r=2.00000000&er=0.06818109&btcer=39413.60840000&ha=MH&hc=19999.00&hs=-1&hq=1
Applied Blockchain, Inc. Launches Mining Operations
Mining is Operational Following Purchase and Installation of $5 Million in Mining Hardware
PR Newswire
DALLAS, Texas , June 25, 2021 /PRNewswire/ -- Applied Blockchain, Inc. ("Applied Blockchain" or the "Company") (PINK: APLD), has announced the commencement of its Ethereum/ Altcoin mining operation. The $5 million in mining hardware acquired by the Company has been installed at a facility in North America . This arrangement is a result of the Company's pivot from its originally planned deployment set to launch in China .
"Despite the logistical and operational challenges it created, pivoting our installation from Asia to North America mid-course was the right decision given current market conditions," said Applied Blockchain, Inc.'s CEO and Chairman, Wes Cummins . "We are now in a solid position to leverage our supply chain and partners to scale hash power rapidly."
Mining operations commenced on June 24, 2021 and once fully ramped, hash power will exceed 200,000 MH/s. The Company's mining assets are powered entirely by low-cost renewable energy and will be managed and optimized by its strategic partners.
https://ir.appliedblockchaininc.com/news-releases/
Where will APLD be in 4 Years?
Hard to say however they hit the ground running hard and fast to help fill the ever growing need for mining/hosting services created by China no longer allow anymore services there and has turned off many.
Here is some interesting information on a block chain infrastructure company started just 4 years ago:
Core Scientific, which started in Seattle but moved HQ to Austin, to go public at a $4.3B valuation
The blockchain infrastructure company announced that it will merge with a SPAC called Power & Digital Infrastructure Acquisition Corp., and go public on the NASDAQ at a $4.3 billion valuation.
Founded in 2017, Core Scientific builds infrastructure technology for bitcoin and other blockchain-related technology. It bills itself as the largest digital asset miner in North America. Revenue is projected at $493 million for 2021 and $1.1 billion for 2022. The company has around 100 employees and has raised $115 million to date, according to PitchBook. It runs 100% net carbon neutral operations.
Power & Digital Infrastructure Acquisition Corp., listed on NASDAQ under the ticker XPDI, is supported by global asset manager BlackRock. The combined company will be led by Levitt and is expected to generate $300 million in net cash proceeds to fund mining equipment purchases and infrastructure. The merger is expected to be completed in the fourth quarter.
Who will help APLD grow GRow GROW?
Some former Core Scientific employees now with APLD:
Nick Phillips, former Chief Operational Officer 2017-2018
Ted Mcleod, Managed the build outs of sites on-site, leading procurement and vendor management 2017-2019
Also we have two Hut 8 former employees Etienne Synman and Roland Davidson.
APLD 2021 market cap 14,564,254
APLD 2025 market cap PRICELESS
NASDAQ $50-$350+ with the cancer treatments successful.
Once QNTA gets the IND approved from the FDA the price of the stock should take off.
Why?
1. There are a lot of eyes on FDA IND approvals.
2. There will be a lot of questions about this particular approval because of the Scorpion Venom.
3. The previous newscasts from previous years will come back into play and I expect there will be current newscasts done at the local, national and international level due to the connection to Covid 19 and the unique solution.
4 The timing come be crucial too as well. QNTA is expected to submit the current requirement in about a month and expect an answer from the FDA within a month after submission. That would be sometime in September 2021 just about the time the "Delta" variant is to peak.
5. Also other products in the company should be taking off as well.
This is a "PERFECT STORM" in the making all to unfold right before out very eyes.
Yes Dr. Chandra said there will be a JOINT PR between Lonza and ENZC.
If they removed the Lonza material from the video then they have some explaining to do.
COLLEGE STATION we have a PROBLEM.
Shit happens and one moves on.
Whether we use Lonza or not is immaterial however it would have been nice with their track record.
We will need a contract manufacturing organization, sometimes called a contract development and manufacturing organization (CDMO) to provide comprehensive services for drug development through drug manufacturing.
Here are some things Dr. Chandra said during last weeks video:
Dr. Chandra said is best during last weeks video:
This is very exciting.
This is a very important milestone for ENZC when a company like Lonza decides to collaborates with us.
This is a very important milestone for ENZC when a company like Lonza decides to collaborates with us.
We have had discussions with large pharmacueticals companies.
There are tremendous interest in both the antibodies.
We have been offered interest in collaboration, partnership/acquisition of assets with a milestone based requirement.
We anticipate there will be a partnership with a larger entity before the twelve period when the IND will be applied on both of the antibodies.
This is a HIGH Risk HIGH REWARD investment. The risk goes down everyday as we move closer to certain milestones.
There are some predictive patterns to how biotech stocks start impressive runs and sometime Big Money loses patience and decides to make a move.
The current company only got started 9 months ago and look at all what it has accomplished. There has been bumps in the road and ENZC made adjustments to continue on to their objectives. One of the biggest setbacks was having to do the clinical trials again in Europe. Charles rolled up his sleeves and figured out what to do.
There will more bumps and more adjustments and I'm confident Charles will figure it out.
The Pot of GOLD is just months away however there will be nuggets leading us there along the way.
It is the pregame announcements..
We haven't even started the 1st quarter yet.
Tee ball 101!
So you say Chandra lied.
How do we know you aren't lying?
Why should anyone believe you?
Chandra is excited about ENZC and with good reason.
Sometimes things don't go as planned.
One thing that is not a lie is ENZC SCIENCE.
We have the technology,
We are producing the product.
ENZC babies are in the incubator and will be available in about 9 months.
Until sigh....
Why with so many "other companies" introducing monoclonal antibodies is ENZC needed?
CEOCFO: What are you looking at regarding COVID?
Mr. Cotropia: We have produced an HIV monoclonal antibody that had been successfully tested in five international labs where it neutralized 95% of all strains against which it was tested. There are 6000 different strains of the HIV virus now known. We know that that our antibody is effective and we know the target site on the virus resulting in neutralization of the HIV virus. For an antibody to be effective it has to attack a neutralizable site on the virus that is always there, does not mutate from strain to strain. Knowing the binding site of our HIV monoclonal antibody, and then examining the CoronaVirus amino acid sequence, a correlation in the structures has been identified by our CSO, Dr. Joseph Cotropia, between the CoronaVirus and the HIV virus. With knowledge of these homologous viral structures, monoclonal antibodies will be created that target the corresponding “Achilles Heel” site on the CoronaVirus, an expected conserved immutable and neutralizable site on the virus. Additionally, using artificial intelligence, we will examine the numerous different strains of the virus to identify other conserved sites and produce additional monoclonal antibody targeting them. This is for the purpose of producing a “collection” or “cocktail” of antibodies for therapeutic use. We recognize that there are now known over 16,000 different variations or strains of the CoronaVirus, each slightly different due to mutation. A successful monoclonal antibody “cocktail” therapy must include multiple antibodies that specifically target several immutable sites and which results in neutralization.
Also, as all experts in the field of monoclonal antibodies agree, including Dr. Anthony Fauci, head of the NIAID/NIH, to have an effective therapy, we must have multiple monoclonal antibodies that target various sites on the virus - and in fact, even President Trump was given a cocktail of two. [color=purple][/color]Therefore, it is imperative to identify conserved neutralizing binding sites on the CoronaVirus, and create multiple monoclonal antibodies that target these critical neutralizable and immutable structures. It is like finding a needle in a haystack and retrieving the needle; you must identify the immutable sites on the virus and then create and characterize fully human monoclonal antibodies that target those sites. [/color]The process described here will be our focus and for the reason that success has already been achieved with regard to the production of broadly neutralizing antibodies directed against the HIV virus, we expect success will likewise be achieved in production of broadly neutralizing human monoclonal antibodies directed against the CoronaVirus.
What happened to Eli Lilly's Coronavirus monoclonal antibody?
FAILURE!!!
On Nov. 9, 2020, based on the totality of scientific evidence available at the time, the FDA issued an EUA to Eli Lilly and Co. authorizing the emergency use of bamlanivimab alone for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Importantly, although the FDA is now revoking this EUA, alternative monoclonal antibody therapies remain available under EUA, including REGEN-COV (casirivimab and imdevimab, administered together), and bamlanivimab and etesevimab, administered together, for the same uses as previously authorized for bamlanivimab alone. The FDA believes that these alternative monoclonal antibody therapies remain appropriate to treat patients with COVID-19 when used in accordance with the authorized labeling based on information available at this time.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab
Then the HAMMER came down:
COMPLETE FAILURE!!!
The Assistant Secretary for Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services are committed to ensuring timely and transparent communication regarding the COVID-19 monoclonal antibody treatments currently authorized for emergency use in certain patients with COVID-19.
Today, we are informing you that ASPR is immediately pausing all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supply of bamlanivimab at a facility for use under EUA 094) on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies, as described below, and not use bamlanivimab and etesevimab administered together at this time.
https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/bamlanivimab-etesevimab-distribution-pause.aspx
So what is Eli Lilly up to now?
Eli Lilly has begun clinical development of an anti-SARS-CoV-2 antibody designed to work against all currently known circulating variants of concern. The action comes weeks after the FDA revoked the single use emergency authorization of Lilly’s first COVID-19 antibody due to the rise of variants.
What about UNKNOWN or FUTURE variants?
Researchers have shown COVID-19 antibodies including Lilly’s bamlanivimab are less effective against variants of concern such as B.1.351 than the original SARS-CoV-2 virus when given as monotherapies. The research, coupled to the emergence of variants of concern as the dominant causes of COVID-19 in parts of the world, has led to reassessments of the use of antibodies as single agents.
AbCellera, which worked with Lilly on bamlanivimab, responded to variants by searching the blood of a patient who recovered from COVID-19 for an antibody that is effective against them. The result is LY-CoV1404, an antibody that binds to a conserved part of the receptor-binding domain.
https://www.fiercebiotech.com/biotech/lilly-takes-variant-busting-covid-19-antibody-into-clinic
What about the other Coronavirus monoclonal antibody from AstraZeneca?
FAILURE!!!
AstraZeneca said on Tuesday a late-stage trial failed to provide evidence that its Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
The study assessed whether the therapy, a cocktail of two types of antibodies, could prevent adults who had been exposed to the virus in the past eight days from developing Covid-19 symptoms.
The therapy, AZD7442, was 33% effective in reducing the risk of people developing symptoms compared with a placebo, but that result was not statistically significant — meaning it might have been due to chance and not the therapy.
The Phase III study, which has not been peer reviewed, included 1,121 participants in the United Kingdom and the United States. The vast majority, though not all, were free of the virus at the start of the trial.
AstraZeneca also said on Tuesday it was in talks with the U.S. government on “next steps” regarding a $205 million deal to supply up to 500,000 doses of AZD7442. Swiss manufacturer Lonza was contracted to produce AZD7442.
https://www.cnbc.com/2021/06/15/astra-antibody-cocktail-fails-to-prevent-covid-19-symptoms-in-trial.html
ENZC is going through the processes to produce monoclonal antibodies
that will be safe, effective against ALL variants known and UNKNOWN.
There is always a possibility that ENZC may be called upon to hurry things up of course with a BLANK CHECK.
No it WON'T.
ENZC is in a good place handling their business as they have always done.
The stock price will trend upward when significant milestones are met.
ENZC have the technology however they have to produce it which takes time like a baby in a womb.
Check back and 9 months and do some research until then and maybe we can have a REAL conversation about how ENZC grew in just 9 months just like a baby in a womb.
Grow baby GROW
Having a the ability to reverse split on the books means absolutely nothing. It is there for POSSIBLE future use.
That being said, if someone don't want to invest in QNTA because of the reverse split possibility so be it. Go and invest elsewhere because when QNTA gets the FDA approval the stock price is going to take off like a bat out hell.
After the FDA approval and the investment community starts to take a closer look at QNTA and invest, one won't be able to buy a share for less than $10.
The bottom line is if anyone don't like the way the company is being ran go invest somewhere else. Dr. M and his peeps have done the grunt work and grew this company to where it is today and will take it to further heights.
CC was very informative.
Company is moving along nicely.
There has been some delays in getting product to the market however that has been clear up and was due to covid.
The KEY to QNTA is getting the FDA approval which is a couple of months away. Hopefully when QNTA run the necessary tests and submit them, the FDA will be swift in their review.
The marketing lady has some good plans in place.
The videos they showed were very informative and somewhat educational.
Who knew about the grapes...
Moving to the QB and the NAZ in the future.